Parmax Pharma Ltd

Parmax Pharma Q1 FY26 Results: Revenue Drops 75% 📉

- Revenue from operations fell sharply to ₹19.4M in Q1 FY26 vs ₹78.2M in Q1 FY25

- Net loss of ₹7.6M this quarter vs net profit of ₹123K same period last year

- Total expenses stood at ₹27.1M, including ₹8.5M materials cost & ₹6.3M employee benefits

- Negative EPS of ₹-2.04 (basic) for the quarter

- ₹3.5 crore insurance claim for Dec 2023 fire incident still pending

- No depreciation on unused clean room & effluent treatment plants

- Results approved by Board on Aug 14, 2025 after audit review